Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-041-4 | CAS number: 102-60-3
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
absorption: ~ 2 % via intestine
distribution: mainly localised within central compartment (minimal tissue distribution)
metabolism: no metabolites detectable
excretion: 92-96 % by renal excretion; 0.35 ml/h
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Pharmacokinetics indicate that ethylenediamine, +4PO is poorly absorbed from the GI tract (less than 2 %), almost exclusively localized in the central compartment (plasma water) with negligible binding to albumin or erythrocytes, minimally biotransformed if at all and removed from the plasma in a simple first order process. 92 - 96 % ethylenediamine, +4PO is eliminated via renal excretion with a rate of 0.35 ml/h by simple glomerular filtration in the absence of tubular reabsorption. The remaining percentages of Ethylenediamine, +4PO may be removed from the body by the biliary pathway.
The logPow of -2.08 and the available data of basic toxicokinetics and acute dermal toxicity (LD50 > 2000 mg/kg bw) do not support a significant absorption through the skin. Most likely, ethlenediamine, +4PO will not difíuse through cellular membranes with ease.
Discussion on bioaccumulation potential result:
Ethylenediamine, +4PO's pharmacokinetics indicate that it is rapidly though poorly absorbed from the GI tract (less than 2 %), almost exclusively localized in the central compartment (plasma water) with negligible binding to albumin or erythrocytes and removed from the plasma in a simple first order process. Ethylenediamine, +4PO is completely eliminated from the bloodstream within the first 24 h.
Discussion on absorption rate:
The available data of basic toxicokinetics (minimal absorption through the GI tract), a LogPow of -2.08 and the data on acute dermal toxicity (LD50 > 2000 mg/kg bw) indicate a negligible absorption through the skin. The available data support the notion that ehtylenediamine, +4PO will not difíuse through cellular membranes with ease.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
